Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Xetra  >  Evotec AG    EVT   DE0005664809

EVOTEC AG (EVT)
Mes dernières consult.
Most popular
Report
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets
Sector news Biotechnology & Medical Research - NEC
08:08a REGENERON PHARMACEUTICALS : Sanofi sees nine regulatory submissions over next 18..
12/12 M&A "boom" dominates Europe share trading as oil leads gains
12/12 Sanofi investors hungry for drug progress and deal news
12/09 Tax-loss selling to pressure 2017's losers in December
11/30 GENMAB : and J&J 'love' partnership as some ponder takeover
11/27 MERCK AND : As Brexit looms, UK pitches new industry plan, wins support from Mer..
11/27 MERCK AND : As Brexit looms, UK pitches new industry plan, wins support from Mer..
11/27DJBIOGEN : Alkermes Join Forces for Multiple Sclerosis Drug
11/27 Regeneron drops eye-drug combination as Novartis chases Eylea
11/24DJBAYER : Amikacin Inhale Fails to Meet Objectives in Phase 3 Trial
11/22 U.S. FDA approves first two-drug HIV regimen in win for GSK
11/16 Recovery rally for European stocks leaves oil sector behind
11/13 Poor earnings updates keep European shares at seven-week low
11/13DJNOVARTIS : Vision Drug Shows Positive Results in Phase 3 Trials
11/03 Prosecutors search Metro offices in insider trading probe
11/01DJAs Experimental Treatments Grow, Families Face Tough Choices
10/31 Pfizer expects broad interest for consumer health business
10/31DJSANOFI : and Regeneron Report Positive Asthma Trial Results
10/27DJMARKET SNAPSHOT : Stock Market Climbs As Tech Rally Powers Gains
10/27DJMARKET SNAPSHOT : Stock Market Climbs As Tech Rally Powers Gains
10/27DJMARKET SNAPSHOT : S&P 500, Nasdaq Climb After Stronger-than-expected GDP, Hot Te..
10/26DJGILEAD SCIENCES : Looks Away From Hepatitis C Treatments for Growth
10/26 GlaxoSmithKline's new boss struggles to sell cure for drugmaker
10/18DJGILEAD SCIENCES : Cell-Therapy Drug Yescarta Gets FDA Approval -- Update
10/18DJGILEAD SCIENCES : Cell-Therapy Drug Yescarta Gets FDA Approval
10/17 Regeneron-Sanofi drug succeeds mid-stage study
10/05DJAppeals Court Rules Against Amgen in Patent Case -- Update
10/05DJAppeals Court Rules Against Amgen in Patent Case
09/29 Merck to stop development of hepatitis C treatments
09/28 Lonza CFO sees in-house growth, not takeovers, to grow drug services
09/20DJSANOFI : Alnylam Report Positive Patisiran Phase III Trial, First-Ever for RNAi ..
08/30DJFDA Approves Pioneering Cancer Treatment With $475,000 Price Tag -- Update
08/30DJFDA Approves Pioneering Cancer Treatment With $475,000 Price Tag
08/29DJGILEAD SCIENCES : Bets $11 Billion On New Cancer Therapy -- WSJ
08/28DJGILEAD SCIENCES : to Buy Kite Pharma for Roughly $11 Billion -- 2nd Update
08/28 Gilead to buy Kite for promising cancer therapies in $12 billion deal
08/28DJGILEAD SCIENCES : The Promising New Cancer Treatment Behind Gilead's $11 Billion..
08/28DJHot Stocks to Watch in the U.S. and Canada
08/28DJGILEAD SCIENCES : to Buy Kite Pharma for Roughly $11 Billion -- Update
08/28DJGILEAD SCIENCES : to Buy Kite Pharma for Roughly $11 Billion in Cash
08/24 Cyclicals boost European shares while Dixons Carphone plummets
08/15 Three CEOs resign from Trump council over Charlottesville
08/14DJHot Stocks to Watch in the U.S. and Canada
08/11DJGILEAD SCIENCES : England's NHS Turns to Clinical Trial to Make Cheaper HIV Drug..
08/11DJGILEAD SCIENCES : England's NHS Turns to Clinical Trial to Make Cheaper HIV Drug..
08/11DJGILEAD SCIENCES : England's NHS Turns to Clinical Trial to Make Cheaper HIV Drug..
07/31 France's Sanofi raises earnings forecast, pleased with eczema drug uptake
07/27DJUNITED THERAPEUTICS : in Settlement Talks With Justice Department -- Update
07/26 Autos and energy firms boost European shares as earnings roll in, banks held ..
07/25DJELI LILLY AND : to Delay Arthritis Drug Application -- Market Talk
Financials (€)
Sales 2017 246 M
EBIT 2017 46,2 M
Net income 2017 28,9 M
Debt 2017 103 M
Yield 2017 -
P/E ratio 2017 71,65
P/E ratio 2018 49,19
EV / Sales 2017 9,13x
EV / Sales 2018 6,81x
Capitalization 2 141 M
Sector Biotechnology & Medical Research - NEC
1st jan.Capitalization (M$)
EVOTEC AG74.01%2 524
CELLTRION, INC.--.--%23 085
IQVIA HOLDINGS INC32.70%21 148
INCYTE CORPORATION-5.43%20 523
LONZA GROUP57.44%19 299
ALNYLAM PHARMACEUTICALS, INC.243.83%12 606
NEKTAR THERAPEUTICS346.86%8 694
ALKERMES PLC-5.04%8 021
SEATTLE GENETICS, INC.8.53%7 954
QIAGEN NV7.36%7 216
SAGE THERAPEUTICS INC206.05%6 705
IONIS PHARMACEUTICALS INC12.75%6 608
EXACT SCIENCES CORPORATION307.49%6 221
ICON PLC47.79%6 008
UNITED THERAPEUTICS CORPORATION-4.43%5 860
PRA HEALTH SCIENCES INC48.04%5 307
CHARLES RIVER LABORATORIES INTL. INC35.36%4 921
BIO-TECHNE CORP25.35%4 758
GALAPAGOS20.51%4 561
INC RESEARCH HOLDINGS INC-24.81%4 283
PUMA BIOTECHNOLOGY INC242.02%3 796